tbuckley/cabot-search huggingface dataset:
The return of acute rheumatic fever in young adults
Authors: M. R. Wallace
Journal: JAMA (1989)

The incidence of acute rheumatic fever (ARF) in the United States has been steadily declining for three decades, and by the mid-1980s had virtually disappeared. In the past 3 years, however, several scattered outbreaks have occurred among US schoolchildren, and there is speculation that ARF will again become a major public health problem in North America. We report a clustering of 10 cases of ARF in young men undergoing basic training at a recruit camp in San Diego, Calif. This was the first such outbreak in two decades among US military personnel and the largest reported series of ARF cases among adults in more than a decade in the United States. Adult-onset ARF was not benign in our patients. The rate of carditis (3 of 10 patients) was similar to that in older studies of adults with ARF. All patients in our series suffered severe polyarthritis, anemia, and fever, but only 60% gave any history of preceding pharyngitis. Rheumatic fever must again be suspected in adults, as well as children, who present with polyarthritis. (<i>JAMA</i>. 1989;262:2557-2561)
American Journal of Cardiology, New York
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Infant death rates
Authors: J. R. Hughes
Journal: JAMA (1971)

<h3>To the Editor.—</h3> Balfe's editorial notes correctly that "<i>Infant mortality is, for the most part, a social rather than a medical problem</i>." But his subsequent statement, "It is time to dispel the idea that it (the infant death rate) is a valid indicator of the health status of the United States population" is misleading. Mr. Balfe compares the demographic and ethnic characteristics of the United States and Sweden, arguing that because Sweden is smaller and has a less-heterogeneous population it should be expected to have a lower infant death rate. Indeed Sweden does enjoy a rate only 60% of the United States rate, but the demographic and ethnic argument explains away very little of this discrepancy. New Hampshire is a small state of about 10,000 sq miles and 700,000 souls, 99% of whom are white, and the vast majority of whom are Christian. It is hilly, rural, and often cold.
poster presentation haematological cancers
Authors: Anita Chandra, Martin Jovitha, P Vijayraghavan, Inrhaoun Hanane, Ibrahim Elghissassi, Hind Elyacoubi, Hassan Errihani, Bensouda Youssef, Wafae Kaikani, Saber Boutayeb
Journal: Annals of Oncology (2009)
A Phase II Expansion Study Of Vorinostat In Combination With Idarubicin and Cytarabine For Patients With Acute Myelogenous Leukemia (AML) With FLT3 Molecular Alterations
Authors: Koichi Takahashi, Elias Jabbour, Farhad Ravandi, Gautam Borthakur, Jorge E. Cortes, Tapan Kadia, Susan O'Brien, Deborah A. Thomas, Stefan Faderl, Joyce Bass, William G. Wierda, Naval Daver, Courtney D. DiNardo, Sherry Pierce, Mark Brandt, Hagop M Kantarjian, Guillermo Garcia-Manero
Journal: Blood (2013)
Abstract 15526: Predictors of Elective Support Device Insertion Prior to High Risk Percutaneous Coronary Intervention: Changing Trends between 1993-2013
Authors: Aatish Garg, Akhil Parashar, Shikhar Agarwal, E. Murat Tuzcu, Samir Kapadia
Journal: Circulation (2014)

Introduction: High risk percutaneous coronary interventions (PCI) may be preceded by elective support device insertion, though the evidence for such a practice is relatively weak. We sought to analyze the changing trends and predictors for prophylactic support device insertion in these patients over the last 20 years. Methods: Retrospective analysis of all patients who underwent PCI at Cleveland Clinic between 1993 - 2013 with or without support device insertion was performed. Trends for device insertion in high risk patients undergoing PCI, like those in clinical shock, acute myocardial infarction (MI) and unprotected left main intervention over the last 20 years were reviewed. Predictors for support device insertion in these patients from 1993-2000 were compared to those from 2001-2013. Results: A total of 666 elective support devices were inserted prior to high risk PCI from 1993-2013. Between 1993-2000, acute myocardial infarction (MI) (OR: 10.05), ejection fraction &lt; 40% (OR: 8.31) and unprotected left main intervention (OR: 4.59) were the three most significant predictors for device insertion prophylactically. Between 2001-2013, unprotected left main intervention (OR: 9.91), ejection fraction &lt; 40% (OR: 5.61) and clinical shock (OR: 5.24) were the biggest predictors, with the odds of support device insertion in acute MI in absence of clinical shock reduced to 1.96. Conclusions: There has been a significant decrease in the proportion of high risk PCIs with elective support device insertion, especially in those performed in patients with acute myocardial infarction in absence of shock.
US-based world medical relief group finds charity begins at home
Authors: A. A. Skolnick
Journal: JAMA (1993)

DOCTORS of the World, an American-based volunteer organization that provides medical and humanitarian relief to desperate populations around the world, is now providing care in its own home town. Doctors of the World, based in New York, NY, was created with the assistance of the French group Médicins du Monde to help American medical professionals find ways to serve the world's neediest people. Since its founding in 1990, the organization has sent physicians and other medical professionals from the United States on missions to Somalia, Ethiopia, South Africa, Tanzania, Cambodia, Iranian Kurdistan, Kenya, El Salvador, Guatemala, Brazil, Russia, and the former Yugoslavia. In August 1992, Doctors of the World set up the first of several programs to provide medical services among drug addicts, political refugees, the homeless, and other disenfranchised populations in New York. These projects currently involve 14 volunteer physicians who are providing health care to drug addicts enrolled
From the National Institutes of Health
Authors: W. Raub
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Minireview: A Skeleton in Serotonin’s Closet?
Authors: Masanobu Kawai, Clifford J. Rosen
Journal: Endocrine Reviews (2010)

Abstract The serotonin molecule plays a multifunctional role in mammalian homeostasis serving as a neurotransmitter in the central nervous system, a gut-derived mediator of peristalsis, and a circulating hormone that regulates appetite, cardiovascular function, and hemostasis. Recent evidence from the clinic and the bench highlight an unexpected target for serotonin action, the skeleton. Clinically, two classes of drugs, the second generation antipsychotic drugs (SGAs) and selective serotonin reuptake inhibitors (SSRIs), which modulate central and peripheral serotonin signaling, have been shown to alter bone remodeling although the mechanism is not clear. In contrast, genetically engineered mouse models have demonstrated a bimodal control system whereby gut-derived serotonin under the control of the Wnt/Lrp/β-catenin system acts systemically to suppress bone formation, whereas CNS serotonin activated by leptin modulates sympathetic outflow to the skeleton. In this brief review, we will summarize recent findings linking serotonin to the skeleton and discuss future directions for this new but challenging aspect of this multidimensional molecule.
Physician requirements in neurology
Authors: M. Menken
Journal: JAMA (1984)

<h3>In Reply.—</h3> Dr Menken makes several points concerning the determination of requirements for the specialty of neurology by the extension of the GMENAC methodology. He believes that the earlier GMENAC estimates were more accurate than the revised numbers in our article. Of note, the original estimates for all of the six specialties discussed were just that —estimates—which were based on a review of the literature and not derived by application of the GMENAC methodology. Thus, the numbers in our article are more accurate in terms of the GMENAC methodology, although not perhaps in Dr Menken's opinion. The methodology did consider referral rates, which Dr Menken believes would be the determining factor of actual requirements for neurologists. Referral rates were one of the variables estimated by the Delphi panelists. Three of the Delphi panelists were primary care physicians, two were general internists, and one was a family physician. These physicians were
Evolution of clinically negative neck. Squamous cell carcinoma of oral cavity and faucial arch
Authors: R. H. Jesse
Journal: JAMA (1971)

The question of whether to electively treat the neck which is clinically negative in patients with squamous cell carcinoma of the oral cavity and faucial arch long has been debated among surgeons and radiotherapists. Some surgeons have found a high incidence of subclinical cancer in the cervical nodes of patients having elective neck dissection, and therefore suggest that radical neck dissection should be done routinely.<sup>5,6</sup>Berger and his co-workers<sup>7</sup>showed that cancer will rarely develop in the electively radiated neck of patients with oropharyngeal and nasopharyngeal cancer, if the tumor dose is 5,000 rads in five weeks or more. Radical neck dissection and radical radiation are not without their complications, and are warranted as an elective treatment only if it can be demonstrated that cervical metastases cannot be successfully managed if they subsequently develop. The policy at the University of Texas MD Anderson Hospital and Tumor Institute, Houston,
MEDICAL NEWS
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Vaccination Coverage Among Children Entering School—United States, 2003-04 School Year
Authors: M Chakarala, G Gugnani, S Gushue, S Kindsfather, A Shukla, M Sullivan, L Vadakara, R Wood, J Blumenstock, A Monaco, L Mascola, J Hadler, D Nguyen, S Schafer
Journal: JAMA (2004)
Environmental Chemical Exposures and Disturbances of Heme Synthesis
Authors: William E. Daniell, Henry L. Stockbridge, Robert F. Labbe, James S. Woods, Karl E. Anderson, D. Montgomery Bissell, Joseph R. Bloomer, Ralph D. Ellefson, Michael R. Moore, Claus A. Pierach, William E. Schreiber, Ayalew Tefferi, Gary M. Franklin
Journal: Environmental Health Perspectives (1997)
Leads from the MMWR. Positive HTLV-III/LAV antibody results for sexually active female members of social/sexual clubs--Minnesota
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
DEATHS
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Council on Pharmacy and Chemistry
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients
Journal: Journal of Clinical Oncology (2010)

The Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST) project aims to additionally explore the data of the two large, randomized, cooperative-group studies comparing two doses of imatinib (400 mg daily v twice daily) in 1,640 patients with advanced GIST.End points were progression-free survival (PFS) and overall survival (OS). Investigated cofactors included age, sex, performance status (PS), primary tumor site, time from diagnosis, prior therapies, baseline biology, and KIT/PDGFRalpha mutations for a subset of 772 patients. Univariate and multivariate models were used for the analysis.At a median follow-up of 45 months, a small but significant PFS advantage was documented for the high-dose arm. OS was identical in the two arms. The multivariate prognostic models included the following adverse factors: male sex, poor PS, and high baseline neutrophils counts (PFS and OS); low hemoglobin and GIST from small bowel origin (PFS); and advanced age, large tumor size, low albumin level, and prior chemotherapy (OS). In patients analyzed for mutations, patients with wild type, patients with KIT exon 9 mutations, and patients with other mutations had worse prognoses than patients with KIT exon 11 mutations for both end points. The mutation status was the only predictive factor for the PFS benefit attributed to high-dose treatment that resulted in significantly longer PFS (and higher objective response rate) for patients with KIT exon 9 mutations.This analysis confirms a small PFS advantage of high-dose imatinib, essentially among patients with KIT exon 9 mutations, but no OS advantage.
FORMIDABLE, BUT NOT FORBIDDING
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cancer Research
Authors: S. Power
Journal: BMJ (1966)

SIR,-Since the beginning of 1965 nearly 30,000 women have had a cervical cytology test under the auspices of the organization known as Cervical Cytology-Cardiff, which is supported financially by the Ministry of Health and the Welsh Hospital Board, the Medical Research Council, and Cardiff City Council.During the past month up to 1,000 smears per week have been examined in the laboratory at St. David's Hospital, Cardiff, and in due course a full report on the scheme will be published.The purpose of this letter is to draw attention to three points that are more often than not completely ignored by those who are more interested in the existence of a cervical cytology service than in its efficiency.(1) A well-staffed central administrative office is essential to-register cases, to notify results to the women and their family doctors, and in due course to arrange for routine repeat examinations.Other responsibilities will depend upon local circumstances-in Cardiff, for example, the central office receives applications and arranges appointments, co-ordinates admission to hospital of Alberta, Canada.
Abstract 19100: Transmural and Lateral Remodeling of the Post-infarction Scar Tissue: Serial Cardiac Magnetic Resonance Imaging Study From the Metocard-Cnic Trial
Authors: Marta Jimenez-Blanco, Rebeca Lorca, Jose Manuel García-Ruiz, Gonzalo Pizarro, Rodrigo Fernández-Jiménez, Ana García-Álvarez, Leticia Fernández-Friera, Valentin Fuster, Borja Ibanez
Journal: Circulation (2015)

Background: The remodeling process that occurs following an acute myocardial infarction produces changes in the myocardial scar and the surrounding tissue. The spatial evolution of the scar has not been yet characterized using MRI. Purpose: To describe the spatial behavior of myocardial scar on its transmural and lateral dimensions following an acute myocardial infarction. Methods: A total of 220 patients with acutely reperfused anterior STEMI (METOCARD-CNIC trial population) were studied. All the patients underwent cardiac MRI at day 7 and 6 months after presentation. The spatial distribution of the scar was analyzed using short axis late gadolinium enhancement images. Endo and epicardial contours of each LV short axis slice was traced, and each one was divided by 100 cords for analysis (Figure 1A). The lateral extension was defined as the percentage of cords with enhancement in every slice, and the transmural extension as the percentage of enhancement within each cord, nested in the lateral extension (Figure 1B). All slices were weighed according to their relative mass. Data were compared by paired t test. Results: Six months after STEMI, myocardial scar was smaller in both dimensions (Figure 1C). Mean ± SEM lateral scar, as a percentage of cords affected, at 7 days and 6 months were, respectively, 27.9 ± 1.1 and 22.2 ± 1.0 (p &lt; 0.001). Transmurality also decreased significantly, mean percentage at day 7 was 46.8 ± 1.5 and at 6 months 35.4 ± 1.4 (p &lt; 0.001). All these changes were accompanied by an increase in LV end-diastolic volume (171.47 ± 2.5 and 190.61 ± 2.9 (p &lt; 0.001)). Conclusions: The myocardial scar remodeling process following a STEMI includes a reduction in both its transmural and lateral extensions.